Current US guidelines recommend absolute risk estimation of cardiovascular disease (CVD) to guide decisions on preventive therapies, but communicating absolute risk alone can be challenging for patients and clinicians.1 In 2021, the European Society of Cardiology guidelines added a recommendation to calculate risk age along with absolute risk to improve communication.2 Risk age represents the… Continue reading #PREVENT Risk Age Equations and Population Distribution in US #Adults
Tag: prevention
#Atherosclerotic #Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations
Key PointsQuestion How do estimates of 10-year atherosclerotic cardiovascular disease (ASCVD) risk and recommendations for primary prevention statin therapy differ between the 2023 American Heart Association (AHA) Predicting Risk of Cardiovascular Disease Events (PREVENT) equations and the 2013 AHA/American College of Cardiology pooled cohort equations (PCEs)?Findings In this cross-sectional study of 3785 adults aged 40 to 75… Continue reading #Atherosclerotic #Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations
Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial
To test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections with the current standard prophylaxis of daily low dose antibiotics. Design Multicentre, open label, randomised, non-inferiority trial. Setting Eight centres in the UK, recruiting from June 2016 to June 2018. Participants Women aged ≥18 years with recurrent urinary tract… Continue reading Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial
2 Medical News 